AU611105B2 - Creation of Inventions and Patents with Artificial Intelligence

AU611105B2 – Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents
– Google Patents

AU611105B2 – Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents
– Google Patents
Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents

Info

Publication number
AU611105B2

AU611105B2
AU80743/87A
AU8074387A
AU611105B2
AU 611105 B2
AU611105 B2
AU 611105B2
AU 80743/87 A
AU80743/87 A
AU 80743/87A
AU 8074387 A
AU8074387 A
AU 8074387A
AU 611105 B2
AU611105 B2
AU 611105B2
Authority
AU
Australia
Prior art keywords
dtpa
polysubstituted
diethylenetriamine
acid
scnbz
Prior art date
1986-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU80743/87A
Other versions

AU8074387A
(en

Inventor
Martin W. Brechbiel
Otto A. Gansow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-09-05
Filing date
1987-09-04
Publication date
1991-06-06

1987-09-04
Application filed by Individual
filed
Critical
Individual

1988-03-24
Publication of AU8074387A
publication
Critical
patent/AU8074387A/en

1991-06-06
Application granted
granted
Critical

1991-06-06
Publication of AU611105B2
publication
Critical
patent/AU611105B2/en

2007-09-04
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid

C07C331/16—Isothiocyanates

C07C331/18—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms

C07C331/22—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

C07C331/24—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

A61K51/04—Organic compounds

A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group

A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3

A61K51/048—DTPA (diethylenetriamine tetraacetic acid)

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

A61K51/04—Organic compounds

A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody

A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C211/00—Compounds containing amino groups bound to a carbon skeleton

C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms

C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton

C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton

C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton

C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated

C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton

C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings

C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C233/00—Carboxylic acid amides

C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups

C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring

C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K2121/00—Preparations for use in therapy

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K2123/00—Preparations for testing in vivo

Abstract

New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.

Description

BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE
BACKGROUND OF THE INVENTION
This invention relates to metal chelates and the formation of metal-chelate protein conjugates. Interest in the art in metal chelates and in methods for forming metal chelate-protein conjugates for diagnostic and therapeutic purposes continues. Representative type chelates and conjugates and methods for forming conjugates are disclosed, inter alia, in U.S. Patents 4,454,106, 4,472,509, 4,339,426. One example of such conjugates is a metal chelate-monoclonal antibody conjugate. Other proteins including antibody fragments, polyclonal antibodies, antigens, blood proteins, or proteins bound to blood lymphocytes or other cells can also be employed in the formation of conjugates. A method for synthesis of bifunctional metal chelates for conjugation to proteins involves reduction of amino acid amides to ethylenediamines to form monosubstituted derivatives which are converted to bifunctional ethylenediaminetetraacetic acid (EDTA) chelates by alkylation with haloacetic acid. (Yeh, et

al . , Anal . Biochem. , 100 : 152, 1979 ) . Similarly,monosubstituted diethylenetriamine is synthesized by reaction of ethylenediamine with an amino acid ester and reduction of the resulting amide carbonyl. (Brechbiel, et al. Inorg. Chem., 25:2772-2781 (1986). Alkylation of the diethylenetriamine with haloacetic acid produces a monosubstituted bifunctional diethylenetriamine- pentaacetic acid (DTPA) chelate. Another method of synthesis of a bifunctional DTPA involves reaction of a DTPA or EDTA carboxylate with an chloroformate ester to form a reactive anhydride. (Krejcarek, et al., Biochem. Biophys Res. Commun., 77: 581, 1977). The dianhydride of DTPA used as a bifunctional chelate is prepared by dehydration of the parent DTPA. (Hnatowich, et al., Int. J. Appl. Rad. Isot., 33:327, 1982). The practice of using an EDTA. chelate monosubstituted at the carbon-1 position to better retard the release of metal from chelate in vitro than the unsubstituted EDTA chelate has also been reported. (Meares, et. al., Anal. Biochem., 142: 68, 1984). Generally, the prior art has formed metal-protein chelate conjugates by mixing monosubstituted bifunctional EDTA or DTPA chelates or DTPA anhydrides with proteins followed by reaction with the metal to be chelated. (Krejcarek, et al., Biochem. Biophys. Res. Commun., 77: 581, 1977); Brechbiel, et al., Inorg. Chem., 25:5783, 1986). Imaging of tumor target sites in vivo with metal chelate conjugated monoclonal antibodies prepared according to these methods has been reported. (Khaw, et al., Science, 209:295, 1980). Sheinberg, et al., Science, 215:1511, 1982). Diagnosis of human cancer in vivo using metal chelate conjugated monoclonal antibody has also been reported. (Rainsbury, et al., Lancet, 2 :

694, 1983). But attempts to employ the tumor localizing properties of metal chelate conjugated monoclonal antibodies for therapeutic purposes have not found common usage, in part because metals may be (and often are) released from the metal chelate conjugate in vivo and, particularly in the case of radioactive metal salts, may produce undesirable concentrations of toxic radionuclides in bone marrow or the like even if the conjugates are rigorously purged of adventitiously bonded metal. A process for purifying metal chelate protein conjugates of adventitiously bonded metals is disclosed in U.S. Patent 4,472,509. The importance of using very strong metal chelates to firmly link radiometals to monoclonal antibodies and of rigorous purification of the conjugates to effect maximal tumor localization and minimize delivery to non-target tissues is discussed in Brechbiel, et al. (Inorg. Chem., 25, 1986). Undesirable localization of potentially therapeutic radionuclides released in mice in vivo from metal chelate conjugated polyclonal antibodies have precluded therapy investigation in humans. (Vaughn, et. al., EIR-Bericht. 78, 1986). Increased in vivo bone uptake of radiometal injected for therapy as a metal chelate conjugated monoclonal antibody has also been reported. (Hnatowich, et al., J. Nucl. Med, 26:503, 1985). The amount of potentially therapeutic doses in humans of radiometal chelated polyclonal antibody has been limited by bone marrow toxicity Order, et al., Int. J. Rad. Oncol., 12: 277, 1986). It is evident from the above that there continues to be a need for more effective metal chelate protein conjugates that firmly link metals to proteins to minimize metal release and permit highly selective delivery of metals to targeted sites in vivo.

SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide novel polysubstituted diethylenetriamines. It is another object of the present invention to provide novel polysubstituted bifunctional diethylenetriaminepentaacetic acid chelates. It is yet another object of this invention to provide novel chelate-protein conjugates. It is a still further object of this invention to provide novel metal chelate protein conjugates. Other objects and advantages of the present invention will become apparent as the detailed description of the invention proceeds.
BRIEF DESCRIPTION OF DRAWINGS
These and other obj ects , features and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings for preparation of compounds of Formula 1, wherein: Fig. 1 shows a scheme for preparation of a polysubstituted diethylenetriamine, where R1 is para-nitrobenzyl and R3,4 are aryl/alkyl groups as described in the text. In the case where R3,4 are the methyl group, the diethylenetriamine product of the scheme is compound (d) of Table 1. Fig. 2 shows a scheme for preparation of polysubstituted diethylenetriamine, where PG represents a protecting group (vide infra), R and R’ are para-nitrobenzyl or aryl/alkyl groups, respectively, as described in the text. In the case where R is

para-nitrobenzyl and R’ methyl, the product diethylenetriamine is compound (a) of Table 1. In the case where R is methyl and R’ is para-nitrobenzyl, the product diethylenetriamine is compound (c) of Table 1.
Fig. 3 shows a scheme for preparation of polysubstituted diethylenetriamine, where PG is a protecting group (vide infra), R is para-nitrobenzyl, R’, R” are alkyl/aryl groups or hydrogen, as described in the text. In the case where R’ is H and R” is methyl, the product diethylenetriamine is compound (b) of Table 1.
FORMULA 1

DETAILED DESCRIPTION OF INVENTION
Unless specifically defined otherwise, all technical or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. An aspect of this invention contemplates the synthesis of diethylenetriamines in which the carbon backbone is polysubstituted but contains at least two substituents. This synthesis is performed by carbodiimide coupling of appropriately substituted alpha amino acid amides with substituted amino acids followed by reduction of the resulting amide to the triamine. Another aspect of the invention contemplates the condensation of an appropriately substituted alpha amino acid with a substituted alpha amino oxime followed by reduction to the desired triamine. A further aspect of this invention contemplates a particularly useful series of bifunctional chelates comprising diethylenetriaminepentaacetic acid substituted on the carbon backbone by at least two side chains (polysubstituted), one of which contains a nitro substitutent. These chelates may be prepared by haloacid alkylation of appropriately polysubstituted diethylenetriamines. In another aspect, the invention contemplates a series of diethylenetriaminepentaacetic acid chelates substituted on the carbon backbone by at least two substituents with one side chain containing a nitro, amino or an isothiocyanate or an N-hydroxysuccinimide ester substituent. In yet another aspect, this invention contemplates protein conjugates of a series of diethylenetriamine

pentaacetic acid chelates substituted on the carbon backbone by at least two substituents. Yet another aspect of this invention contemplates metal chelate conjugated proteins formed by conjugation to protein of a series of diethylenetriaminepentaacetic acid chelates or metal chelates substituted on the carbon backbone by at least two substituents which are not H. More particularly, the present invention provides metal chelate conjugated proteins, especially metal chelate conjugated monoclonal antibodies or antibody fragments, which retain their biological activity and specificity, are substantially free of adventitously bonded metals, and which in vivo retain the metal tied to the protein better than the conjugates known in the prior art. Metals which are released in vivo can be bound by transferrin, metallόthionen or other metal binding proteins (e.g. ferritin) which are present in the blood. Such metals are retained in the circulatory system often for long periods of time arid are cleared to various organs of the reticuloendothelial system (RES), to the bone, bone marrow or to kidney. Such clearance results in a concentration of the metal in the liver, spϊeen, kidney, bone or bone marrow. It is apparent that random, long term circulation of radiometals or concentration of radioactive materials in non-targeted organs such as liver, spleen, bone, bone marrow or kidney are highly undesirable. It is an object of the present invention to alleviate such serious problems. A large number of bifunctional chelates which have been indicated to be useful in conjugating metals, especially radiometals, to proteins are not sufficiently strong to adequately retain metals in vivo for use in diagnosis. Thus bifunctional EDTA comlexes of Indium de-metallate in a mouse model, as do anhydride linked DTPA complexes of Indium (Brechbiel, et al. 25 Inorg. Chem. 1986). Prior art DTPA-containing protein conjugates have coupled the DTPA through a carboxylate group of the DTPA

or through a functional group on a side chain attached to a nitrogen of the DTPA. These chelates are not as stable as the backbone polysubstituted chelates of the present invention. A backbone monosubstituted DTPA has also been coupled to proteins but yttrium and bismuth complexes of that chelate are not as stable as those of the chelates of the present invention. Preferred embodiments and a detailed explanation of the invention are provided in the following description, and utility further delineated by the accompanying examples.
PREFERRED EMBODIMENTS OF THE INVENTION
In accordance with the present invention, the bifunctional chelate has, as one portion of its structure, a side chain linked to a carbon atom of the chelate backbone which serves to sterically hinder the conformational opening of the chelate structure required for release of a metal from the chelate. Any of a variety of side chains may be employed, the choice being within one of ordinary skill in the art. The side chain may contain carbon to carbon or ether, linkages or the like. Hydrocarbon side chains are preferred. If there are heteroatoms present, for example in ether linkages, they may be counted as carbon atoms for the purpose of chain length determinations. Such structures include, without limitation, straight or branched chain alkyl groups having 1 to about 15 carbon atoms such as methylene, ethylene, propylene, butylene, isopropylene and the like; a straight or branch chain alkene group having 1 to about 15 carbon atoms including ethene, propene, butene and the like and isomers thereof; aryl groups including phenyl, diphenyl, napthyl and the like; and alkyl aryl groups having 1 to about 15 carbon atoms in one or more branched or straight chain alkyl groups, including benzyl, phenyl ethylene, phenyl propylene and the like. The side chain should be essentially free of

reactive groups, especially those easily reduced by hydrogen and hydride reagents. Preferred side chains include straight or branched chain alkanes with 5 or less carbons, benzyl, and phenylethylene. A most preferred such side chain is the methyl group as denoted in Table 2 and Formula 2, 3. The bifunctional chelates of this invention have in another portion of their molecular structure a substituent with a reactive functional group attached to a carbon atom of the chelate backbone and which reacts directly with amino acid residues of a protein to form a covalent linkage. Such reactive functional groups include isothiocyanate, the N-hydroxysuccinimide ester and haloacetamide. The reactive functional group, according to the practice of this invention, may be attached directly to the chelate backbone or may be attached through a wide variety of side chains. Any of a wide variety of side chains may be employed and the choice of a particular one will be within the skill of the art. Hydrocarbon side chains are preferred. If there are heteroatoms present, for example in ether linkages, interrupting the carbon backbone, they may be counted as carbon atoms for the purpose of chain length determinations. Such structures include, without limitation, straight or branch chain alkyl groups having 1 to about 15 carbon atoms such as methylene, ethylene, propylene, butylene, isopropylene and the like; a straight or branch chain alkene group having 1 to about 15 carbon atoms including ethene, propene, butene and the like and isomers thereof; aryl groups including phenyl, diphenyl, napthyl and the like; and alkyl aryl groups having 1 to about 15 carbon atoms in one or more branched or straight chain alkyl groups, including benzyl, phenyl ethylene, phenyl propylene and the like. The essential purpose of this side chain is only to serve as a stable link between the chelate and the functional group. The side chain should be essentially free of reactive groups other than the desired functional groups as described

above. Preferred side chains include substituted straight chain alkanes, benzyl, and phenylethylene. In a preferred aspect of this invention, diethylenetriamines of the structure shown in formula (1), with the substituents of Table 1 as intermediates in the preparation of the polysubstituted DTPA derivatives of Formulas 2, 3 are desired. Prefered chelates are represented in Formula 2. In formula (2), X is preferably haloacetamide, isothiocyanate or N-hydroxysuccinimide and R1-R4, R1′-R4′ are H, or alkyl groups with 5 or less carbon atoms, irrespective of isomeric structure or permutation and n=5. In another preferred aspect of this invention, chelates of the structure shown in formula 3 are desired, where X, R1-R4, R1′-R4′ and n are the same as in formula 2. Most preferred for the practice of this invention are the compounds of formula 2 and 3 wherein the substituents are as shown in Table 2 and referred to as compounds 2(a), 2(b), 3(c) and 2(d).

The introduction of reactive side chains into the carbon backbone structure of chelates has been described in the prior art. (Meares, et. al. 142 Anal. Biochem. 68, 1984). Essentially all syntheses of DTPA have as their penultimate reaction step the alkylation of a parent diethylenetriamine. Thus the methods for preparation of carbon backbone polysubstituted DTPA reduces to the preparation of the parent diethylenetriamines. The conventional method for preparation of a substituted diethylenetriamine is illustrated in Fig. 1. The process consists of reaction of an amino acid ester with an ethylenediamine followed by reduction to the diethylenetriamine. The reactions of Fig. 1 can be used to provide a novel compound 1(d) of Table 1 wherein R is para-nitrobenzyl and R3, R4are methyl. In accordance with this scheme, 2,3-diaminobutane may be reacted with p-nitrobenzylalanine methyl ester and the product reduced with diborane to provide the parent diethylenetriamine of 2(d). To produce 2(d), the nitrogens of the parent diethylenetriamine are alkylated with bromoacetic acid, the nitro group is then catalytically reduced with hydrogen, and the resulting amine reacted with thiophosgene. solution with the desired protein at a pH of from about 6 to about 11, most preferably at a pH of from about 7 to about 9.5. Desirably, the pH is adjusted with buffered solutions such as a bicarbonate buffered solution. Once again, the choice of an appropriate buffer is within the skill of the art. The temperature of the solution can range from just above freezing to the temperature at which the chelate becomes unstable or the protein denatures. Often temperatures above 37°C tend to denature proteins. The metal chelate protein conjugate of this invention may be used as such with appropriate pH adjustment, if needed. Alternatively, if it is desired

to purify the conjugate from unconjugated chelate or products of any side reactions, the product may be purified. A variety of standard purification techniques known in the art may be used including column chromatography and high-performance liquid chromatography (HPLC). The invention contemplates an in vivo therapeutic procedure in which radiometal chelate conjugated monoclonal antibodies are introduced into the body and allowed to concentrate in the target region. There are a wide variety of radiometal isotopes which form stable DTPA complexes and emit cytotoxic beta particles, positrons, Auger electrons and alpha particles. Useful beta particle emitting isotopes include Sc-46, Sc-47, Sc-48, Ga-72 and Ga-73 and Y-90. Bi-212 is a useful alpha emitter. The therapeutic effect occurs when the conjugates are near or in contact with and bind to the targeted cells. Cell death may be a direct or indirect result of the radiation event of the radiometal which is positioned in close proximity to the cell. The benefits of this aspect of the invention are several. First, the high specificity of the conjugated monoclonal antibody minimizes the total radiation dosage. Only enough radiation for the target cells need be employed. In addition, radiometal chelates generally are cleared rapidly from the body should the conjugated antibody be disrupted. The isotope can be short-lived and the affinity constant by which the isotope is retained in the chelates is very high resulting in a stably bound metal. Additionally, since the amount of radiometal employed is minimized, the radiation hazard to persons preparing and administering the radiometal chelate conjugated antibody is significantly reduced. Because of the properties of the radiometal chelate conjugated monoclonal antibody employed by the present invention, tissue damage or whole body dose during therapy are markedly reduced as compared to that from presently employed methods of radiation therapy such

as isotope implants, external radiation therapy, and immunoradiotherapy employing iodine-131 labeled polyclonal or autologus antibodies. Additionally, both biological and physical half-lives of the targeting radiobiological may now be controlled, minimizing whole body radiation effects. Since radiation is targeted to specific cell types (such as neoplastic cells) a therapeutic dose is delivered specifically to malignant cells, either localized or metastasized. The ability of radiometal chelate conjugated monoclonal antibody to provide an effective dose of therapeutic radiation specifically to metastasized cells is also unique and singularly useful for cancer therapy. In another embodiment, the present invention contemplates an in vivo diagnostic procedure which comprises introducing a metal chelate conjugated monoclonal antibody into the body, allowing sufficient time for the conjugate to localize and identifying the degree and the site of localization, if any. The present invention also contemplates in vivo analytical procedures employing a chelate conjugated monoclonal antibody. The conjugated antibody of the present invention is substantially free of adventitiously or weakly chelated metal. The chelates conjugated to the antibody in the present invention is a derivative of diethylenetriaminepentaacetic acid (DTPA). Other diagnostic and therapeutic techniques are described in U.S. Patent 4,454,106, which is incorporated herein by reference. The following examples are to be used for illustrative purposes only are and not to be limiting to the scope of this invention.

EXAMPLES
Example 1
Preparation of 1,(2)-methyl-4-p-isothiocyanato benzyl)diethylenetriaminepentaacetic acid. (The mixture of geometric isomers of compounds 2(a), 2(b) in Table 1.
Methyl p-nitrophenylalanine hydrochloride Dry methanol (200 ml) was saturated with HCl(-g) in a two-necked round bottom flask cooled to -10°C. p-Nitrophenylalanine (10.0 g, 47.6 mmol) was added in one portion and left to stir for about 18 hours, the solution was evaporated to near dryness on a rotary evaporator and the precipitated product collected in a Buchner funnel. After drying under vacuum at about 50°C, the yield was 10.97 grams (88.3%). A TLC (thin layer chromatography) of the free amino ester run in CHCl3:MeOH (4:1) revealed an Rf= 0.85-0.88. 1H NMR (220 MHz, D2O, pH 1.5) 8.20 (d,2 J=10.0), 7.53 ( d,2, J=10.0), 4.55 (t, 1,J=5.00), 3.84 (s,3), 3.43 (m,2); CI-MS 225 ((M+1)/z). Anal. Calcd. for C10H13N2O4Cl: C, 46.07; H, 5.03; N, 10.74; Cl, 13.60. Found: C, 45.87; H, 5.08; N, 10.48; Cl, 13.58.
N-(2-amino-[1(2)-methyl]ethyl)-p-nitrophenylalanine amide Methyl p-nitrophenylalanine hydrochloride (9.80 g, 37.63 mmol) was treated with triethylamine (6.78 ml, 45.2 mmol) to liberate the amino ester. After removal of the solvent, the residual oil was then added dropwise in methanol (5 ml) to 1,2-diaminopropane (50 ml) at room temperature (20°-24°C) while vigourously stirring. After stirring 18 hours, the excess solvent was removed via rotary evaporation at 50°C at .01 mm of vacuum until a constant weight was achieved (10.01 g,

96%). TLC of the product in CHCl3:MeOH (4:1) on silica revealed an Rf=0.10-0.12. 1H NMR (220 MHz, D ), pH 10.0) 8.06 (d,2,J=7.5), 7.41 (d,2,J=7.5), 3.72 (t,1,J=8.0), 3.18-2.73 (m,5), 0.918 (m,3); CI-MS 267 ((M+1)/z). Anal. Calcd. for C12H18N4O3: C, 54.53; H, 6.77; N, 21.05. Found: C, 54.33; H,6.76; N, 20.92.
1(2)-Methyl-4-(p-nitrobenzyl)diethylenetriamine trihydrochloride
N-(2-amino-[1(2)-methyl]ethyl)-p-nitrophenylalanine amide (9.90 g, 37.2 mmol) was reduced with 1M (boronhydride tetrahydrofuran) BH3THF (200 mL). A one liter three-neck round bottom flask was fitted with a reflux condenser, septum, argon inlet and bubbler exit, and flame dried. The amide (8.12 g, 38.9 mmol) was washed into the reaction flask with dry tetrahydrofuran THF (150 ml) and cooled to -10°C. Next, 1 M BH3THF solution (200 ml) was added with a syringe. The reaction solution was stirred one hour at -10°C, then raised to a gentle reflux for 18 hours, after which it was cooled to -10°C and dry methanol (25 ml) was injected. The solution was brought to room temperature and stripped to near dryness. Methanol (25 ml) was again added and the solution evaporated to near dryness. Cleavage of the borane aggregate required a vigorous reflux of the HC1 saturated ethanolic solution plus the addition of concentrated aqueous HCl ( 5ml). The product precipitated cleanly and after cooling to 0°C for 6 hours was collected and dried under vacuum (11.60 g, 86.3%). CI-MS 362 ((M+1)/z). Anal. Calcd. for C12H23N4O2Cl3: C, 39.85; H, 6.65; N, 15.49. Found: C, 39.99; H, 6.64; N, 15.14.
1(2)-Methyl-4-(p-nitrobenzyl)diethylenetriaminepentaacetic acid: The parent diethylenetriamine (1.0 g, 2.77 mmol) was treated with bromoacetic acid (5.767 g, 41.5

mmol) and 7N KOH ( 13.04 ml). The reaction solution was allowed to stir for 72 hours at room temperature. The solution was acidified to pH 1.5 with concentrated HBr and extracted with ether (3 X 100 ml). The aqueous solution was evaporated to a solid and loaded onto a 2.6 x 30cm ion exchange column AG50W X 8, 200-400 mesh, H+ form, (BioRad Inc., Richmond CA) and washed with H2O to remove the unreacted materials, hydrolysis products and salts. The crude product was eluted with 2N aqueous NH3. The crude product was further purified by HPLC using a 10 x 250 mm, C18 reverse phase column with a 25 minute gradient of aqueous .05M triethylammonium acetate to 100% methanol at a flow rate of 3 ml/min. The product had a retention time of 9.1 minutes. The combined fractions from the HPLC were re-chromatographed on an AG50W X 8 column as specified above to remove the triethylammonium acetate buffer. The product was collected and the solvent evaporated to a solid. (.648 g, 43.2%).
1(2)-Methyl-4-(p-aminobenzyl)diethylenetriaminepentaacetic acid The parent nitrobenzyl DTPA (100.0 mg, 0.1845 mmol) was hydrogenated with Pd/C. A water-jacketed three-neck flask (50 ml) was charged wtih 10% Pd/C(43mg), H2O (5ml) and a stirring bar. The center neck was attached to an atmospheric hydrogenation apparatus, one side neck was fitted with an injection valve, and the remaining neck was firmly stoppered. The assembled hydrogenation apparatus was evacuated and flushed with hydrogen while the reaction flask was cooled to 4°C. The nitrocompound was dissolved in H2O (10ml) and 5M NaOH was added to bring the pH to 10.0. The solution was injected into the reaction flask and hydrogen uptake monitored. After the reaction, the mixture was filtered through a fine frit with Celite 535 (Fluka AG, Switzerland). The solvent was removed and the residue dried under vacuum for 18 hours with yield being essentially quantitative.

1(2)-Methyl-4-(p-isothiocyanatobenzyl)diethylenetriamine- pentaacetic acid (The mixture of compounds, a,b in Table 2.) The parent mixture of aniline precursors to compound 2(a), 2(b) and described above (0.095 g, 0.1845 mmol) was dissolved in H2O ( 5ml ) pH 8.5 and converted to a crude product by treatment with thiophosgene (0.212 g, 1.845 mmol) in CHCl3(10 ml). The crude product was purified by column chromatography on a 1 x 30 cm Florisil (Sigma, St. Louis, Mo) column eluted with CH3CN:H2O (30:8) with the product eluting first. The solvent was removed with minimum heating and the remaining aqueous solution lyophilized overnight. The Rf of the product on silica using CH3CN:H2O (30:8) was 0.20. The IR spectrum possessed the characteristic absorption at 2100 cm-1for the isothiocyanate.
Example 2
Compound 2(d) of Table 2 is prepared by the method of example 1 by simply substituting 2,3-diaminbbutane for 1,2-diaminopropane in the second step of the synthesis.
Example 3
Preparation of 1-p-isothiocyantobenzyl)-3-methyl DTPA. (Synthesis of compound 2(a) in Table 1 as a single geometric isomer).
t-Butoxycarbonyl-(d,1)-p-nitrophenylalanine: p-Nitrophenylalanine (7.94 g, 37.8 mmol) was dissolved in 50% aqueous dioxane solution (60 ml) and triethylamine (7.9ml, 56.7 mmol) added [2-(t-butoxycarbonyloxyamino)2- phenylacetonitrile]. (10.24 g, 41.6 mmol, Aldrich Chemical Co. ) was added and the solution stirred for two hours. Ethyl acetate (100 ml) and H2O (50 ml) were added and the contents poured into a separatory funnel. The aqueous layer was retained and extracted twice with

ethyl acetate (100 ml). The aqueous layer was cooled to 0°C and the pH was adjusted to 2.0 with 3N HCl, whereupon a precipitate formed which was collected and dried under vacuum. The filtrate was extracted with ethyl acetate twice (100 ml), dried over MgSO4and stripped to dryness. The two fractions proved to be identical and were combined (11.0 g, 94.0%). The melting point of the compound was 165°C. 1H NMR (220 MHz, DMSO-d6 ) 8.036 (d, 2,J=8.00), 7.29 (d,2, J=8.00), 5.38 (d, I, J=8.00), 4.44 (m,l),3.25 (dd,l,J=13.0,6.00), 3.05 (dd,l, J=13.0, 6.00), 1.39 (s,9); CI-MS 311 ((M+1)/z).
t-Butoxycarbonyl-(dl)-p-nitrophenylalaninyl-(1)-alanine amide: BOC-(dl)-p-nitrophenylalanine (10.0 g, 32.26mmol), l-alanine amide hydrobromide (5.45 g, 32.26mmol), triethylamine (4.487 ml, 32.36 mmol), and l-hydroxybenzotriazole (3.84 g, 28.4 mmol) were dissolved in ethyl acetate (400 ml). Dicyclohexylcarbodiimide (7.30 g, 35..44 mmol) in ethyl acetate (25 ml) was added and the reaction mixture was allowed to stir for 18 hours after which three drops (about 0.15 ml) of concentrated acetic acid were added. The dicyclohexylurea was filtered off and the filtrate was extracted sequentially with saturated sodium chloride salt solution (100 ml), 1N HCl (3 x 100 ml), saturated salt solution (100 ml), 5% NaHCO3(3 x 100 ml), and saturated salt solution (100 mL). The organic solution was dried over MgSO4, filtered, and reduced to 50 ml. Petroleum ether (50 mL) was added and the contents of the flask were cooled to OºC for 12 hours. The precipitate was collected on a Buchner funnel and dried under vacuum (10.55 g, 86.1 %). 1H NMR (220 MHz, CDCl3/d6-DMSO) 8.08 (d,2,J=9.0), 7.91 (m,l), 7.45 (d,2,J=9.0), 7.14 (d, 1, J=12.0), 6.68 (m,2), 4.35 (m,2), 3.17 (dd, 1,J=15.0,6.0), 2.98 (dd,1.J=15.0, 8.0), 1.38 (s,9); CI-MS 381 ((M+1)/z). Anal. Calcd. for

C17H24N4O6: C, 53.68; H, 6.31; N, 14.73. Found: C, 53.92; H, 6.59; N, 14.84.
2-Methyl-4-(p-nitrobenzyl)diethylenetriamine trihydrochloride: The dipeptide amide described above (5.10 g, 13.42 mmol) was deprotected by treatment with trifluoroacetic acid (50 ml) for one hour after which the solution was rotary evaporated to near dryness. Methanol (50 ml ) was added and the solution was taken to dryness. The resulting solid was held at .01 mm and 50°C for 8 hours to insure removal of the residual acid. The resulting ammonium salt (5.10 g, 13.42 mmol) in THF (50 ml) was added to a flame dried 250 ml three neck flask fitted with a condenser under argon atmosphere. The flask was cooled to 0°C and 1M BH3THF (30.8 ml) was added via syringe. The reaction solution was heated to a vigorous reflux for two hours and then allowed to stir at room temperature for an additional two hours. The reaction flask was cooled to 0°C and methanol (25 ml) was slowly injected to decompose excess hydride. The solution was reduced to dryness, taken up in absolute ethanol (50 ml), and concentrated HCl (50 ml) was added. The solution was vigorously refluxed for two hours and then stripped to dryness. The residue was dissolved in H2O, loaded onto a 1.5 x 20 cm AG50W X8, H+ form, ion exchange column, and washed with H2O until the eluant was neutral. The product was eluted from the column with concentrated HCl (125 ml), concentrated to 10 ml, and lyophilized overnight. The remaining solid was found to be substantially pure (1.823 g, 66.2%). 1H NMR (500 MHz, D2O, pH 1.0) 8.268 (d,2,J=8.0), 7.614 (d,2,J=8.0), 4.106 (m,l), 3.773 (m,l), 3.680-3.450 (m,3), 3.393 (m,l), 3.312 (m,l), 3.212 (m,l), 1.493 (br. t,3); (500 MHz, D2O, pH 11.0) 8.091 (d,2,J=8.0), 7.438 (d,2,J=8.0), 3.167 (m,l), 2.910 (m,l), 2.75-2.45 (overly complicated multiplet, 6), 1.031 (br.

s, 3); CI-MS 253 ((M+l)/z). Anal. Calcd. for C12H23N4O2Cl3: C, 39.85; H, 6.36; N, 15.49. Found: C, 39.88; H, 6.36; N, 15.28. Conversion of this diethylenetriamine to compound 2(a) was achieved by the method described in Example 1.
Example 4
Preparation of 1-p-isothiocyanatobenzyl-4-methyl DTPA (compound 2(b) prepared as a pure geometric isomer following the scheme shown in Fig. 3).
BOC-p-nitrophenylalanine 2-oxopropyl amide
t-Butyloxycarbonyl-p-nitrophenylalanine (4.42g, 14.26 mmol, aminoacetone hydrochloride (1.56 g, 14.26 mmol), triethylamine (1.44 g, 14.26 mmol), 1-hydroxybenzotriazole (1.69 g, 12.55 mmol), were dissolved in ethyl acetate (400 ml). 1,3-Dicγclohexylcarbodiimide (3.23 g, 15.68 mmol) in ethyl acetate (25 ml) was added and the solution allowed to stir for 18 hours. Glacial acetic acid (0.2 ml) was added and the solution was filtered. The filtrate was extracted with saturated salt solution ( 100 ml ), 1N HCl solution (3×100 ml), saturated salt solution (100 ml), 5% bicarbonate solution (3×100 ml), and saturated salt solution (100 ml ). The organic phase was dried over MgSo4, filtered and concentrated to 50 ml. Petroleum ether (50 ml) was added and the solution was cooled to 0°C for 12 hours. The precipitated product was collected and dried under vacuum.
BOC-p-nitrophenylalanine-2-(oxime methyl ether) propyl amide The ketone (2.00 g, 5.47 mmol) was dissolved in pyridine (10 ml) and methoxylamine hydrochloride (0.914 g, 10.95 mmol) was added. The solution was allowed to stir for 12 hours after which the solvent was removed.

The residue, was dissolved in minimal ethyl acetate and crystallized by addition of petroleum ether to yield the oxime ether amide.
1-Methyl-4-(p-nitrobenzyl)diethylenetriamine trihydrochoride The oxime ether (3.00 g, 7.61 mmol) was deprotected by stirring with neat trifluoroacetic acid (10 ml ). The solvent was removed by high vacuum rotary evaporation. The residue was dissolved in tetrahydrofuran ( 50 ml) and added to a flame dried flask fitted with a reflux condenser, an argon inlet and bubbler exit, and an injection port. The solution was cooled to 0°C and 1M BH3THF (200 ml) was added via syringe. The reaction was refluxed for 6 hours, cooled to 0°C, and methanol (25 ml) was added decomposing any excess hydride. The solution was rotary evaporated to near dryness and the residue was taken up in ethanol (100 ml). The ethanol solution was saturated with HCl(g) and refluxed for four hours, after which the solution was cooled for 18 hours at 0°C. The precipitate was collected, washed with diethyl ether, and dried under vacuum. Conversion of this diethylenetriamine to compound 2(b) was achieved by the method described in Example 1.
Example 5
A monoclonal antibody specific for the Rauscher leukemia virus was labeled with a mixture of the chelates a and b of Table 2 as follows. The antibody was suspended in a buffered normal saline solution having a pH of about 8.5. The chelates were added in aqueous solution. This protein solution after reaction overnight was purified by dialysis against metal free 0.05 M citrate, 0.15 M NaCl buffer, pH 5.5. Before labeling with metal, the protein was dialysed against a solution

comprising 0.02 M N-morpholinoethanesulfonic acid and 0.08 M in acetate, pH 5.9. To label with Yttrium-90, the protein solution was reacted with an acetate solution of the isotope at pH ranging about 4 to 5.5 and purified by passage through a TSK 3000 size exclusion column (Beckman Inc., Berkley, CA) and by dialysis. When the labeled antibody thus prepared was injected into mice bearing spleens invaded with the Rauscher leukemia virus, the antibody was seen to localize in the spleen with about 30% of injected dose bound to the tumorous spleen and only 1-2% of the radioactive dose was found in the bone, where it would destroy bone marrow. In contrast, antibody labeled by using the mixed anhydride of DTPA of prior art, when labelled with Y-90 as above and injected into the same mouse tumor model, also localized in the spleen to about the same degree but with about 8-12% of injected radioactive dose being undesirably found in bone marrow (data not shown). In a separate study, antibody was labeled with Bismuth-212 or Bi-206 by reaction of iodide solutions of the isotopes with the antibody prepared with chelates 2a, 2b as described in Table 2. These preparations were also injected into mice and tissue distribution data showed that 5-10% of the dose was found in kidney, the natural repository of unchelated bismuth. However, antibody labeled by use of the mixed anhydride chelate of prior art lose as much as 50% of the dose to kidney during the same time causing kidney damage. Labelling with other radioactive isotopes is similarly done and tests on the target tissue or organ similarly performed. These studies demonstrate the remarkable utility of the chelates of the present invention for use in specifically transporting therapeutic isotopes to tumors while minimizing the distribution of the compounds to non-targeted organs such as kidney and bones. Imaging of the target tissue or organ can, of course, be done by standard radiographic techniques well known in the art.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims (14)

WHAT IS CLAIMED IS:

1. A method for preparing polysubstituted diethylenetriaminepentaacetic acid chelate comprising the sequential steps of (a) reacting an amino-protected alpha amino acid with an amino acid amide, (b) deprotecting the protected amino acid; (c) reducing the product obtained in step (b) to produce polysubstituted diethylenetriamine; (d) converting said diethylenetriamine to desired polysubstituted diethylenetriaminepentaacetic acid or an ester thereof by alkylating with a haloacetic acid or haloacetate ester.

2. A method for preparing polysubstituted diethylenetriaminepentaacetic acid chelate comprising the steps of (a) reacting an amino protected alpha amino acid with an alpha aminoketone; (b) converting the resulting ketone to an oxime ether by reaction with methoxylamine; (c) deprotecting the resulting oxime ether and then reducing the deprotected oxime ether to produce diethylenetriamine which, after alkylation with a haloacetic acid or ester yields the desired polysubstituted diethylenetriaminepentaacetic acid or an ester thereof.

3. A polysubstituted diethylenetriaminepentaacetic acid (DTPA) of following formula 2 or 3 having one side chain attached to the carbon backbone of the DTPA and containing a functional group which is stable in aqueous solution at a pH value within the range of about 1-7 and which reacts directly with amino acid residues of a protein to form a stable covalent linkage at conjugating pH values from about 6-11 and which has one or more additional side chains containing from 1-8 carbon atoms linked to the carbon backbone of the DTPA:

4. The polysubstituted DTPA of Claim 3 wherein the functional group is a haloacetamide.

5. The polysubstituted DTPA of Claim 3 wherein the functional group is an isothiocyanate.

6. The polysubstituted DTPA of Claim 3 wherein the functional group is an N-hydroxysuccinimide ester.

7. The polysubstituted DTPA of Claim 3 wherein the R1-R4,R’1-R’4groups are as follows:
wherein SCNBz is para-isothiocyanatobenzyl group .

8. The DTPA of Claim 3 being conjugated with a protein.

9. The DTPA of Claim 8 wherein said protein is a mono- or poly-clonal antibody or a fragment thereof.

10. The DTPA of Claim 9 being radiolabelled.

11. The DTPA of Claim 10 wherein radiolabel is selected from the group consisting of In-111, Y-90, Bi-212, Ga-68 and Sc-47.

12. A method of delivering radiolabelled compound to a target site in a host comprising administering to a host an amount of the compound of Claim 11 effective to produce radiotherapeutic or radioimaging effect at a target site in said host.

13. A polysubstituted diethylenetriamine of the following formula having at least two side chains attached to the carbon backbone of the triamine and containing a nitro group:

14. The polysubstituted diethylenetriamine of Claim 13 wherein the R1 -R4,R ‘ 1-R’ 4groups are as follows :
R1’R1′ R2,R2′ R3,R3′ R4,R4′
SCNBz, H H, H CH3, H H, H
SCNBz, H H, H H, H CH3, H
H, H SCNBz, H H, H CH3, H
SCNBz, H H, H CH3, H CH3, H
wherein SCNBz is para-isothiocyanatobenzyl group ,

AU80743/87A
1986-09-05
1987-09-04
Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents

Ceased

AU611105B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US903723

1986-09-05

US06/903,723

US4831175A
(en)

1986-09-05
1986-09-05
Backbone polysubstituted chelates for forming a metal chelate-protein conjugate

CA000594072A

CA1338721C
(en)

1986-09-05
1989-03-17
Backbone polysubstituted chelates for forming a metal chelate-protein conjugate

Publications (2)

Publication Number
Publication Date

AU8074387A

AU8074387A
(en)

1988-03-24

AU611105B2
true

AU611105B2
(en)

1991-06-06

Family
ID=25672531
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU80743/87A
Ceased

AU611105B2
(en)

1986-09-05
1987-09-04
Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents

Country Status (9)

Country
Link

US
(1)

US4831175A
(en)

EP
(1)

EP0328529B1
(en)

JP
(2)

JP2555391B2
(en)

KR
(1)

KR920003590B1
(en)

AT
(2)

ATE137214T1
(en)

AU
(1)

AU611105B2
(en)

CA
(1)

CA1338721C
(en)

DE
(3)

DE3751788T2
(en)

WO
(1)

WO1988001618A1
(en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5246692A
(en)

1986-09-05
1993-09-21
The United States Of America As Represented By The Secretary Of Health And Human Services
Backbone polysubstituted chelates for forming a metal chelate-protein conjugate

US5227474A
(en)

1987-02-13
1993-07-13
Abbott Laboratories
Bifunctional chelating agents

US5057302A
(en)

1987-02-13
1991-10-15
Abbott Laboratories
Bifunctional chelating agents

IE980697A1
(en)

1988-10-31
2000-12-13
Dow Chemical Co
Chelants possessing ortho ligating functionality and complexes thereof

US5696239A
(en)

1988-10-31
1997-12-09
The Dow Chemical Company
Conjugates possessing ortho ligating functionality and complexes thereof

US5342604A
(en)

1988-10-31
1994-08-30
The Dow Chemical Company
Complexes possessing ortho ligating functionality

US5686410A
(en)

1989-07-20
1997-11-11
Novartis Ag
Polypeptide derivatives

US5124471A
(en)

1990-03-26
1992-06-23
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Bifunctional dtpa-type ligand

US5494935A
(en)

1992-01-17
1996-02-27
University Of Utah Research Foundation
Methods for oral decorporation of metals

US5403862A
(en)

1992-01-17
1995-04-04
University Of Utah Research Foundation
Method for oral decorporation of metals

US7744877B2
(en)

1992-11-13
2010-06-29
Biogen Idec Inc.
Expression and use of anti-CD20 Antibodies

AU688743B2
(en)

1992-11-13
1998-03-19
Biogen Idec Inc.
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

DK1974747T3
(en)

1998-08-11
2012-09-17
Biogen Idec Inc

Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

BR9915164A
(en)

1998-11-09
2003-01-07
Idec Pharma Corp

Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody

WO2000027433A1
(en)

1998-11-09
2000-05-18
Idec Pharmaceuticals Corporation
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants

MY133346A
(en)

1999-03-01
2007-11-30
Biogen Inc
Kit for radiolabeling ligands with yttrium-90

US20020102208A1
(en)

1999-03-01
2002-08-01
Paul Chinn
Radiolabeling kit and binding assay

US6207858B1
(en)

1999-03-03
2001-03-27
Idec Pharmaceuticals Corporation
Regioselective synthesis of DTPA derivatives

EP2264070A1
(en)

1999-08-11
2010-12-22
Biogen-Idec Inc.
Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody

US8557244B1
(en)

1999-08-11
2013-10-15
Biogen Idec Inc.
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

EP1918305A1
(en)

1999-08-11
2008-05-07
Biogen Idec Inc.
New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

US6682902B2
(en)

1999-12-16
2004-01-27
Schering Aktiengesellschaft
DNA encoding a novel RG1 polypeptide

JP2003531178A
(en)

2000-04-25
2003-10-21
アイデックファーマスーティカルズコーポレイション

Intrathecal administration of rituximab for the treatment of central nervous system lymphoma

JP4202127B2
(en)

2000-10-02
2008-12-24
ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド

B cell malignancy treatment method using antagonist anti-CD40 antibody

US20020159996A1
(en)

2001-01-31
2002-10-31
Kandasamy Hariharan
Use of CD23 antagonists for the treatment of neoplastic disorders

EP1372724A2
(en)

2001-01-31
2004-01-02
Idec Pharmaceuticals Corporation
Use of immunoregulatory antibodies in the treatment of neoplastic disorders

IL157145A0
(en)

2001-01-31
2004-02-08
Idec Pharma Corp
Use of dc23 antagonists for the treatment of neoplastic disorders

US20030003097A1
(en)

2001-04-02
2003-01-02
Idec Pharmaceutical Corporation
Recombinant antibodies coexpressed with GnTIII

WO2003000647A1
(en)

2001-06-22
2003-01-03
Schering Ag
(ethylene)-(propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents

US20030194371A1
(en)

2001-07-10
2003-10-16
Schering Ag
(Ethylene)-(propylene) – triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents

TWI284539B
(en)

2001-07-30
2007-08-01
Epix Pharm Inc
A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide

EA007905B1
(en)

2001-11-16
2007-02-27
Байоджен Айдек Инк.
Polycistronic expression of antibodies

US20080063639A1
(en)

2002-01-18
2008-03-13
Pierre Fabre Medicament
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies

AU2003228269A1
(en)

2002-03-01
2003-09-16
Mds Proteomics Inc.
Phosphorylated proteins and uses related thereto

JP2006520194A
(en)

2003-01-27
2006-09-07
バイオジェン・アイデック・エムエイ・インコーポレイテッド

Compositions and methods for treating cancer using IGSF9 and LIV-1

DE10305463A1
(en)

2003-02-04
2004-08-12
Schering Ag

Enantiomerically pure (4S, 8S) – and (4R, 8R) -4-p-nitrobenzyl-8-methyl-3,6,9-triza-3N, 6N, 9N-tricarboxymethyl-1,11-undecanedioic acid and their derivatives, process for their manufacture and use for the manufacture of pharmaceutical compositions

DE10305462A1
(en)

2003-02-04
2004-08-12
Schering Ag

Conjugates of enantiomerically pure (4S, 8S) – and (4R, 8R) -4-p-benzyl-8-methyl-3,6,9-triaza-3N, 6N, 9N-tricarboxymethyl-1,11-undecanedioic acid with biomolecules, method for their manufacture and use for manufacture

EP1613750B1
(en)

2003-03-19
2015-10-14
Amgen Fremont Inc.
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

NZ544911A
(en)

2003-07-22
2008-12-24
Schering Ag
RG1 antibodies and uses thereof

CN1929862B
(en)

2003-11-04
2012-02-15
诺华疫苗和诊断公司
Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia

SI1694360T1
(en)

2003-11-04
2010-12-31
Novartis Vaccines & Diagnostic
Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection

CA2544368C
(en)

2003-11-04
2014-04-01
Chiron Corporation
Methods of therapy for b cell-related cancers

PT1684805E
(en)

2003-11-04
2010-10-26
Novartis Vaccines & Diagnostic
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma

ATE476991T1
(en)

2003-11-04
2010-08-15
Novartis Vaccines & Diagnostic

METHOD FOR TREATING SOLID TUMORS WITH EXPRESSION OF CD40 CELL SURFACE ANTIGEN

JP2007513072A
(en)

2003-11-05
2007-05-24
パリンゲンインコーポレーテッド

Enhanced B cell cytotoxicity in CDIM binding antibodies

WO2005084179A2
(en)

2003-12-01
2005-09-15
Immunomedics, Inc.
Improved method for preparing conjugates of proteins and chelating agents

FR2873699B1
(en)

2004-07-29
2009-08-21
Pierre Fabre Medicament Sa

NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF

DK1814913T3
(en)

2004-11-05
2015-09-28
Univ Leland Stanford Junior
ANTIBODY-INDUCED CELL membrane damage.

JP2008520616A
(en)

2004-11-24
2008-06-19
アプラーゲンゲゼルシャフトミットベシュレンクテルハフツング

Solid phase peptide synthesis and purification method

ATE476994T1
(en)

2004-11-30
2010-08-15
Curagen Corp

ANTIBODIES TO GPNMB AND THEIR USES

EA200701448A1
(en)

2005-01-05
2008-02-28
Байоджен Айдек Эмэй Инк.

SPECIFICALLY CONNECTED TO OUR MOBILE COURSE.

FR2888850B1
(en)

2005-07-22
2013-01-11
Pf Medicament

NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS

EP1957115B8
(en)

2005-11-10
2014-03-05
Celldex Therapeutics, Inc.
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen

FI20055653A
(en)

2005-12-08
2007-06-09
Wallac Oy

The labeling reagent

DOP2006000277A
(en)

2005-12-12
2007-08-31
Bayer Pharmaceuticals Corp

ANTI MN ANTIBODIES AND METHODS FOR USE

US7727525B2
(en)

2006-05-11
2010-06-01
City Of Hope
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics

GB0700133D0
(en)

2007-01-04
2007-02-14
Humabs Llc
Human cytomegalovirus neutralising antibodies and use thereof

US20100092384A1
(en)

2007-03-19
2010-04-15
The Junited States Of America As Represented By Secretary, Dept. Of Health And Human Service
Multifunctional nanoparticles and compositions and methods of use thereof

EP2014681A1
(en)

2007-07-12
2009-01-14
Pierre Fabre Medicament
Novel antibodies inhibiting c-met dimerization, and uses thereof

WO2009012288A2
(en)

2007-07-17
2009-01-22
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging

JP5659014B2
(en)

2007-08-02
2015-01-28
ジリードバイオロジクス，インク．

Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis and metastasis

US9446995B2
(en)

2012-05-21
2016-09-20
Illinois Institute Of Technology
Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions

US10189803B2
(en)

2008-02-22
2019-01-29
Illinois Institute Of Technology
Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions

BRPI0916443A2
(en)

2008-07-16
2017-10-31
Inst Res Biomedicine

human cytomegalovirus neutralizing antibodies and their use

JP5475774B2
(en)

2008-07-16
2014-04-16
インスティテュートフォーリサーチインバイオメディシン

Human cytomegalovirus neutralizing antibody and use thereof

US8871207B2
(en)

2008-07-25
2014-10-28
Humabs, LLC
Neutralizing anti-influenza A virus antibodies and uses thereof

CN102164613B
(en)

2008-07-25
2014-11-26
生物医学研究所
Neutralizing anti-influenza a virus antibodies and uses thereof

EP2172485A1
(en)

2008-10-01
2010-04-07
Pierre Fabre Medicament
Novel anti CXCR4 antibodies and their use for the treatment of cancer

NZ592054A
(en)

2008-10-13
2013-06-28
Inst Research In Biomedicine
Dengue virus neutralizing antibodies and uses thereof

US8545839B2
(en)

2008-12-02
2013-10-01
Pierre Fabre Medicament
Anti-c-Met antibody

AR074439A1
(en)

2008-12-02
2011-01-19
Pf Medicament

ANTI-CMET ANTIBODY (C-MET RECEIVER)

US20120003235A1
(en)

2008-12-31
2012-01-05
Biogen Idec Ma Inc.
Anti-lymphotoxin antibodies

EP2308897A1
(en)

2009-10-09
2011-04-13
Pierre Fabre Medicament
Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer

US20110212106A1
(en)

2010-01-20
2011-09-01
Institute For Research In Bioscience
Hiv-1 neutralizing antibodies and uses thereof

EP2371863A1
(en)

2010-03-30
2011-10-05
Pierre Fabre Médicament
Humanized anti CXCR4 antibodies for the treatment of cancer

EP2455403A1
(en)

2010-11-23
2012-05-23
Pierre Fabre Medicament
Homogeneous humanized antibodies against JAM-A that inhibit proliferation

US9738707B2
(en)

2011-07-15
2017-08-22
Biogen Ma Inc.
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto

DK2734545T3
(en)

2011-07-18
2019-04-15
Inst Res Biomedicine

NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND APPLICATIONS THEREOF

TWI606064B
(en)

2012-02-08
2017-11-21
Ｉｇｍ生物科技公司
Cdim binding proteins and uses thereof

ES2657470T3
(en)

2012-03-20
2018-03-05
Humabs Biomed S.A.

Antibodies that neutralize RSV, MPV and PVM and their uses

WO2013180730A1
(en)

2012-06-01
2013-12-05
Lawrence Lowell Jeffry
Large-scale high yield manufacturing process for high purity pentaalkyl esters of dtpa

PT3052192T
(en)

2013-10-02
2020-09-24
Medimmune Llc
Neutralizing anti-influenza a antibodies and uses thereof

WO2015051362A1
(en)

2013-10-04
2015-04-09
Illinois Institute Of Technology
Multifunctional chelators, complexes, and compositions thereof, and methods of using same

CA2954780A1
(en)

2014-07-15
2016-01-21
Medimmune, Llc
Neutralizing anti-influenza b antibodies and uses thereof

WO2016055950A1
(en)

2014-10-08
2016-04-14
Novartis Ag
Combination of human cytomegalovirus neutralizing antibodies

WO2016075546A2
(en)

2014-11-14
2016-05-19
Antonio Lanzavecchia
Antibodies that neutralize ebola virus and uses thereof

CN114805558A
(en)

2014-11-18
2022-07-29
胡默波斯生物医学公司
Antibodies that strongly neutralize rabies and other lyssaviruses and uses thereof

WO2016100615A2
(en)

2014-12-18
2016-06-23
The University Of Chicago
Methods and composition for neutralization of influenza

EP3960761A1
(en)

2015-06-01
2022-03-02
MedImmune, LLC
Neutralizing anti-influenza binding molecules and uses thereof

US20180179274A1
(en)

2015-06-26
2018-06-28
Institute For Research In Biomedicine
Proteins comprising a mutated lair-1 fragment and uses thereof

WO2017059878A1
(en)

2015-10-07
2017-04-13
Humabs Biomed Sa
Antibodies that potently neutralize hepatitis b virus and uses thereof

NZ743713A
(en)

2015-12-15
2020-01-31
Gilead Sciences Inc
Human immunodeficiency virus neutralizing antibodies

WO2017123685A1
(en)

2016-01-13
2017-07-20
Medimmune, Llc
Method of treating influenza a

WO2018010789A1
(en)

2016-07-13
2018-01-18
Humabs Biomed Sa
Novel antibodies specifically binding to zika virus epitopes and uses thereof

WO2018044812A2
(en)

2016-08-29
2018-03-08
Fred Hutchinson Cancer Research Center
Chelating platform for delivery of radionuclides

SG11201909265QA
(en)

2017-04-19
2019-11-28
Inst Res Biomedicine
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

GB201710973D0
(en)

2017-07-07
2017-08-23
Avacta Life Sciences Ltd
Scaffold proteins

WO2019042555A1
(en)

2017-08-31
2019-03-07
Humabs Biomed Sa
Multispecific antibodies specifically binding to zika virus epitopes and uses thereof

WO2019169231A1
(en)

2018-03-02
2019-09-06
The University Of Chicago
Methods and composition for neutralization of influenza

CA3121004A1
(en)

2018-12-19
2020-06-25
Humabs Biomed Sa
Antibodies that neutralize hepatitis b virus and uses thereof

MX2022002231A
(en)

2019-08-29
2022-03-22
Vir Biotechnology Inc
Antibody compositions and methods for treating hepatitis b virus infection.

GB202101299D0
(en)

2020-06-09
2021-03-17
Avacta Life Sciences Ltd
Diagnostic polypetides and methods

US20230242621A1
(en)

2020-06-24
2023-08-03
Vir Biotechnology, Inc.
Engineered hepatitis b virus neutralizing antibodies and uses thereof

KR20230141754A
(en)

2020-10-30
2023-10-10
아박타 라이프 사이언시스 리미티드

FAP-activated serum half-life extended therapeutic conjugate

WO2022164805A1
(en)

2021-01-26
2022-08-04
Vir Biotechnology, Inc.
Compositions and methods for treating hepatitis b virus infection

CA3172265A1
(en)

2021-03-10
2022-09-15
Dimitri BIELI
Antibodies against tdp-43 and methods of using the same

WO2022234003A1
(en)

2021-05-07
2022-11-10
Avacta Life Sciences Limited
Cd33 binding polypeptides with stefin a protein

TW202332694A
(en)

2021-10-07
2023-08-16
英商阿凡克塔生命科學公司
Serum half-life extended pd-l1 binding polypeptides

WO2023057567A1
(en)

2021-10-07
2023-04-13
Avacta Life Sciences Limited
Pd-l1 binding affimers

WO2023218243A1
(en)

2022-05-12
2023-11-16
Avacta Life Sciences Limited
Lag-3/pd-l1 binding fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4454106A
(en)

1982-06-07
1984-06-12

Gansow Otto A

Use of metal chelate conjugated monoclonal antibodies

US4472509A
(en)

1982-06-07
1984-09-18

Gansow Otto A

Metal chelate conjugated monoclonal antibodies

AU1833288A
(en)

1987-06-24
1989-01-05

Dow Chemical Company, The

Functionalized polyamine chelants and rhodium complexes thereof and process for their preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4622420A
(en)

1980-03-18
1986-11-11
The Regents Of The University Of California
Chelating agents and method

NL8204108A
(en)

1981-10-27
1983-05-16
Hybritech Inc

IMAGING TUMOR WITH RADIOACTIVELY MARKED MONOCLONAL ANTIBODIES.

SE8301395L
(en)

1983-03-15
1984-09-16
Wallac Oy

KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES

1986

1986-09-05
US
US06/903,723
patent/US4831175A/en
not_active
Expired – Lifetime

1987

1987-09-04
EP
EP87906504A
patent/EP0328529B1/en
not_active
Expired – Lifetime

1987-09-04
AU
AU80743/87A
patent/AU611105B2/en
not_active
Ceased

1987-09-04
AT
AT91122418T
patent/ATE137214T1/en
not_active
IP Right Cessation

1987-09-04
AT
AT92114713T
patent/ATE144496T1/en
active

1987-09-04
KR
KR1019880700490A
patent/KR920003590B1/en
not_active
IP Right Cessation

1987-09-04
DE
DE3751788T
patent/DE3751788T2/en
not_active
Expired – Lifetime

1987-09-04
JP
JP62505982A
patent/JP2555391B2/en
not_active
Expired – Lifetime

1987-09-04
DE
DE3788961T
patent/DE3788961T2/en
not_active
Expired – Lifetime

1987-09-04
DE
DE3751936T
patent/DE3751936T2/en
not_active
Expired – Lifetime

1987-09-04
WO
PCT/US1987/002207
patent/WO1988001618A1/en
active
IP Right Grant

1989

1989-03-17
CA
CA000594072A
patent/CA1338721C/en
not_active
Expired – Fee Related

1996

1996-03-12
JP
JP8055048A
patent/JP2659351B2/en
not_active
Expired – Lifetime

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4454106A
(en)

1982-06-07
1984-06-12
Gansow Otto A
Use of metal chelate conjugated monoclonal antibodies

US4472509A
(en)

1982-06-07
1984-09-18
Gansow Otto A
Metal chelate conjugated monoclonal antibodies

AU1833288A
(en)

1987-06-24
1989-01-05
Dow Chemical Company, The
Functionalized polyamine chelants and rhodium complexes thereof and process for their preparation

Also Published As

Publication number
Publication date

DE3751936D1
(en)

1996-11-28

DE3751788D1
(en)

1996-05-30

WO1988001618A1
(en)

1988-03-10

DE3788961T2
(en)

1994-07-14

DE3751788T2
(en)

1996-11-28

JPH02501385A
(en)

1990-05-17

ATE144496T1
(en)

1996-11-15

JP2659351B2
(en)

1997-09-30

DE3751936T2
(en)

1997-04-03

CA1338721C
(en)

1996-11-12

JP2555391B2
(en)

1996-11-20

JPH08231474A
(en)

1996-09-10

DE3788961D1
(en)

1994-03-10

AU8074387A
(en)

1988-03-24

KR880701708A
(en)

1988-11-04

EP0328529B1
(en)

1994-01-26

US4831175A
(en)

1989-05-16

ATE137214T1
(en)

1996-05-15

EP0328529A4
(en)

1991-03-20

KR920003590B1
(en)

1992-05-04

EP0328529A1
(en)

1989-08-23

Contact information